|
Volumn 50, Issue 3, 2002, Pages 171-178
|
A phase I study of the GM-CSF antagonist E21R
a b b b c d c a a a a a a b a a e e e e more.. |
Author keywords
E21R; GM CSF; Pharmacokinetics; Phase I; Prostate
|
Indexed keywords
E21R;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR;
PROSTATE SPECIFIC ANTIGEN;
PROTEIN INHIBITOR;
RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
UNCLASSIFIED DRUG;
ADULT;
AGED;
AREA UNDER THE CURVE;
ARTHRALGIA;
ARTICLE;
BREAST CARCINOMA;
CELL PROLIFERATION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COLON CARCINOMA;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOSE CALCULATION;
DOSE RESPONSE;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG EFFECT;
DRUG HALF LIFE;
DRUG SAFETY;
DRUG TOLERABILITY;
EOSINOPHILIA;
ERYTHEMA;
FEMALE;
HUMAN;
HUMAN CELL;
INJECTION SITE;
LETHARGY;
LUNG CARCINOMA;
MALE;
MAXIMUM TOLERATED DOSE;
MELANOMA;
MYALGIA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CARCINOMA;
PROTEIN EXPRESSION;
RECTUM CARCINOMA;
SOLID TUMOR;
THIRST;
TREATMENT OUTCOME;
WORLD HEALTH ORGANIZATION;
ADULT;
AGED;
AGED, 80 AND OVER;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ERYTHEMA;
FATIGUE;
FEMALE;
GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT;
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
MALE;
MIDDLE AGED;
NEOPLASMS;
PAIN;
RECOMBINANT PROTEINS;
|
EID: 0036046483
PISSN: 03445704
EISSN: None
Source Type: Journal
DOI: 10.1007/s00280-002-0474-y Document Type: Article |
Times cited : (8)
|
References (20)
|